ANA

Patients with advanced Alzheimer's disease treated with 13.3 mg rivastigmine patch showed greater improvements in cognitive, functional, and behavioral performance from baseline compared to patients who received 4.6 mg patches.

Despite current guideline recommendations against the use of routine neuroimaging for uncomplicated headaches, physicians still tend to order imaging tests for many patients who present with headache and migraine, driving up annual healthcare spending.

Study results show that patients who received combination treatment demonstrated improvements in cognition, function, and behavioral outcomes compared to treatment with either medication alone or placebo.

Patients with advanced Parkinson's disease treated with an investigational extended-release carbidopa-levodopa formulation experienced greater reductions in "off" time and greater improvement in dyskinesia-free "on" time compared with similar patients treated with carbidopa-levodopa plus entacapone.

Results from the first multi-center interventional trial in premanifest HD research show that the antioxidant Coenzyme Q10 is associated with only mild or moderate side effects, even at higher doses.

Study results indicate a significant correlation between depression and hallucination in patients with Parkinson's disease, while anxiety is a significant predictor for both the number and severity of hallucinations.

Study shows that the use of telemedicine by primary stroke centers and other hospitals increases access to specialized stroke care for patients living in rural and medically underserved areas.

Study results show that a structured educational intervention for staff aimed at improving knowledge of pain assessment and treatment has little effect on outcomes as measured by pain scores.

Correlation between change in brain volume and a clinical measure of cognitive function could be potential marker for clinical progression of multiple sclerosis.